In vitro chemosensitivity testing of human non-small cell lung cancer cell lines

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3181-3185

  Bepler, Gerold ^a   O'Briant, Kathy ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clonogenic assay; Drug testing; Irinotecan; Non small cell lung cancer; Paclitaxel; Small cell lung cancer; Vinorelbine

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CYTOSTATIC AGENT; DACTINOMYCIN; DAUNORUBICIN; ETOPOSIDE; IRINOTECAN; MITHRAMYCIN; PACLITAXEL; TENIPOSIDE;

ARTICLE; CHEMOSENSITIVITY; CLONOGENIC ASSAY; DRUG SCREENING; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0031730642     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Holmes EC, Livingston R, and Turrisi A: Neoplasm of the thorax. In: Cancer medicine (Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, and Weichselbaum RR, eds.). Philadelphia, Lea and Febiger, 1993, pp 1285-1337.
2. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1997. Calif Cancer J Clin 47: 5-27, 1997.
3. Girling DJ, Stott H, Stephens RJ, and Fox W: Fifteen-year follow-up of all patients in a study of post-operative chemotherapy for bronchial carcinoma. Br J Cancer 52: 867-873, 1985.
4. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, and Hill DP: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633-641, 1988.
5. Souquet PJ, Chauvin F, Boissel JP, Cellerino TR, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, and Bernard JP: Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 342: 19-21, 1993.
6. Ramanathan RK and Belani CP: Chemotherapy of advanced non-small cell lung cancer: past, present, future. Semin Oncol 24: 440-448, 1997.
7. Bepler G, Koehler A, Kiefer P, Havemann K, Beisenherz K, Jaques G, Gropp C, and Haeder M: Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation 37: 158-171, 1988.
8. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH, and Minna JD: Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45: 2913-23, 1985.
9. Loh PM, Clamon GH, Robinson RA, White ML, Hukku B, Rossi NP, and Peterson WD: Establishment and characterization of four new human non-small cell lung cancer cell lines. Cancer Res 44: 3561-3569, 1984.
10. Ruckdeschel JC, Oie HK, and Gazdar AF: in vitro characterization of non-small cell lung cancer. In: Lung cancer: basic and clinical aspects (Hansen HH, ed.). Boston, Martinus Nijhoff Publishers, 1986, pp 49-59.
11. Siegfried JM: Detection of human lung epithelial cell growth factors produced by a lung carcinoma cell line: use in culture of primary solid lung tumors. Cancer Res 47: 2903-2910, 1987.
12. Carmichael J, Mitchell JB, DeGraff WG, Gamson J, Gazdar AF, Johnson BE, Glatstein E, and Minna JD: Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer 57: 540-547, 1988.
13. Mogi H, Hasegawa Y, Watanabe A, Nomura F, Saka H, and Shimokata K: Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro. Cancer Chemother Pharmacol 39: 199-204, 1997.
14. Simmonds AP, Hamilton PS, Kerr H, Harvey K, Moyes P, Davidson KG, and Faichney A: Drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media. Br J Cancer 54: 587-594, 1986.
15. Salmon SE: Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep 68: 117-125, 1984.
16. Shoemaker RH, Wolpert-DeFilippes MK, Kern DH, Lieber MM, Makuch RW, Melnich NR, Miller WT, Salmon SE, Simon RM, Venditti JM, and Von Hoff DD: Application of a human tumor colony-forming assay to new drug screening. Cancer Res 45: 2145-2153, 1985.
17. Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, and Makuch R: Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 70: 1027-1032, 1981.
18. Weisenthal LM, Marsden JA, Dill PL, and Macaluso CK: A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 43: 749-757, 1983.
19. Shaw GL, Gazdar AF, Phelps R, Linnoila, RI, Idhe DC, Johnson BE, Oie HK, Pass HI, Steinberg SM, Ghosh BC, Walsh TE, Nesbitt JC, Cotelingam JD, Minna JD, and Mulshine JL: Individual chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivitytesting. CancerRes 53: 5181-5187, 1993.
20. Carney DN, Mitchell JB, and Kinsella TJ: in vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res 43: 2806-2811, 1983.
21. Alberts DS and Chen HSG: Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: Cloning of human tumor stem cells (Salmon SE, ed.). New York, Alan R Liss, 1980, pp 352-358.
22. Ehninger G, Proksch B, Heinzel G, and Woodward DL: Clinical pharmacology of mitoxantrone. Cancer Treat Rep 70: 1373-1382, 1986.
23. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, and Harrap KR: Pharmacokinetics of cis-diammine-l,l-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res 44: 1693-1698, 1984.
24. Hori T, Muraoka K, Saito Y, Sasahara K, Inagaki H, Inoue Y, Adachi S, and Anno Y: Influence of modes of ACNU administration on tissue and blood drug concentration in malignant brain tumors. J Neurosurg 66: 372-376, 1987.
25. Preusser P, Pielken HJ, and Bauch HJ: Pharmacokinetic study of cytosine arabinoside in patients with acute myelogenous leukemia. Haematol Blood Transfus 30: 288-292, 1987.
26. Weenen H, Lankelma J, Penders PGM, McVie JG, Ten Bokkel Huinink WW, de Plangue MM, and Pinedo HM: Pharmacokinetics of 4'-epi-doxorubicin in man. Invest New Drugs 1: 59-63, 1983.
27. Woolley C and Pittillo RF: Microbiological assay and tissue distribution of mithramycin (NSC-24559) in mice. Cancer Chemother Rep 55: 311-316, 1974.
28. Dhingra HM, Valdivieso M, Carr DT, Chiuten DF, Farha P, Murphy WK, Spitzer G, and Umsawasdi T: Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 3: 176-183, 1985.
29. LeChevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, and Tursz T: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367, 1994.
30. Ruckdeschel JC, Finkelstein DM, Mason BA, and Creech RH: Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V-a randomized comparison of four cisplatin-containing regimens. J Clin Oncol 3: 72-79, 1985.
31. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, and Vogl S: A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4: 14-22, 1986.
32. Hill BT (1983) Use of continuous human tumour cell lines to evaluate drugs by clonogenic assays. In: Human tumour drug sensitivity testing in vitro (NN, eds.). London, Academic Press, 1983, pp 129-141.
33. Ihde D, Russell E, Oie H, Linnoila L, Steinberg S, Ghosh B, Cotelingham J, Minna J, and Gazdar A: Prospective trial of chemotherapy based on in vitro drug sensitivity testing in extensive stage small cell lung cancer. Lung Cancer 4: A101, 1988.
34. Boyd MR: The NCI in vitro anticancer drug discovery screen. In: Anticancer drug development guide: preclinical screening, clinical trials, and approval (Teicher B, ed.). Totowa, Humana Press Inc, 1998, pp 23-42.
35. Davis S, Tonato M, Crino L, Colozza MA, Lubanski K, and Grignani F: Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. Cancer 58: 1018-1019, 1986.
36. Giaccone G, Donadio M, Ferrati P, Bonardi G, Ciuffreda L, Bagatella M, and Calciati A: Teniposide in the treatment of non-small-cell lung carcinoma. Cancer Treat Rep 71: 83-85, 1987.
37. Kreisman H, Ginsberg S, Propert KJ, Richards F, Graziano S, and Green M: Carboplatin or iproplatin in advanced non-small cell lung cancer: a cancer and leukemia group B study. Cancer Treat Rep 71: 1049-1052, 1987.
38. Kenis Y and Brule G: Preliminary clinical screening with daunorubicin in lung cancer. Eur J Cancer 6: 155-156, 1970.